Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-10

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke

NCT04950790

Acute Ischemic Stroke

UNKNOWN PHASE4

Pilot Investigation of Stem Cells in Stroke

NCT01151124

Stroke

COMPLETED PHASE1

Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke

NCT06551727

Stroke, Ischemic

ENROLLING_BY_INVITATION NA

For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.

NCT05068349

Stroke Cerebral Infarction Brain Infarction +4 more

RECRUITING PHASE4

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

NCT06238024

Interleukin-6 Ischemic Stroke Endovascular Treatment

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pentoxifylline

Group Type EXPERIMENTAL

Pentoxifylline

Intervention Type DRUG

Take pentoxifylline 0.4 g twice daily

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pentoxifylline

Take pentoxifylline 0.4 g twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CSPC Pharmaceutical Group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Han Chinese, age 40-80 years old, male and female, right-handed;
* The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021;
* NIHSS score 1-15 points;
* Daily Living Ability Scale (ADL) ≥75 score;
* The Informed consent signed by the patient or his legal representative

Exclusion Criteria

* Can not cooperate with the examination (including neuropsychological tests and scale assessment);
* There were memory disorders, dementia with lewy bodies and frontotemporal dementia before the onset of stroke events;
* There were definite infectious diseases 2 weeks before admission; Have a serious mental illness, previous history of cancer, alcohol or drug abuse;
* Use of drugs that may affect cognitive function, including sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, and cholinoid drugs;
* Can not accept brain MRI examination

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No